Expression And Clinical Significance Of CD133and MACC1in Rectal Cancer After Neoadjuvant Chemoradiotherapy

Objective: To investigate the expression of CD133and MACC1in rectal cancer andtheir relationship with the prognosis of rectal cancer after neoadjuvantchemoradiotherapy.Methods: Immunohistochemical (IHC) staining for CD133and MACC1wereperformed in166surgically resected rectal cancers from The Affiliated UnionHospital of Fujian Medical University during2007to2011. There were82patientsreceived neoadjuvant chemoradiotherapy (CRT) and84patients underwentnon-chemoradiotherapy (Non-CRT). The expression of CD133and MACC1betweenCRT group and Non-CRT group were analyzed.Results: According to the results of immunohistochemical staining, CD133expressedmore frequently in the CRT group than in the Non-CRT group (68.3%vs34.5%,P<0.01), whereas MACC1expressed more frequently in the Non-CRT group than inthe CRT group (53.7%vs75.0%, P<0.01). The overexpression of CD133wassignificantly correlated with the ypT stage, RCRG stage and recurrence or metastasisof rectal cancer in the CRT group(P<0.05).On the other hand, the overexpression ofMACC1was correlated with the ypT stage, ypN stage, ypTNM stage and recurrenceor metastasis of rectal cancer in the CRT group(P<0.05),but no correlations werefound with other clinicopathological parameters(P>0.05). Univariate survival analysisshowed that the significant prognostic factors in the CRT group were ypT stage, ypNstage, ypTNM stage, positive expression of CD133and MACC1(P<0.05).Multivariate analysis showed that CD133, ypT stage and ypN stage were independentprognostic factors in the CRT group(P<0.05).Conclusions: High expression of CD133and/or MACC1in rectal cancer afterneoadjuvant chemoradiotherapy induce poor prognosis, rectal cancer stem cells may playing an role of chemotherapy resistance on the tumor tissue. CD133can be used topredict prognosis in patients of rectal cancer after neoadjuvant chemoradiotherapy.